TL;DR
Semaglutide produced an average of 14.9% body weight[1] loss over 68 weeks in the STEP-1 trial at the 2.4 mg dose. One-third of participants lost 20% or more. Semaglutide is the generic name for the active ingredient in Wegovy, Ozempic, and compounded formulations.
Below you'll find dose breakdowns, month-by-month timelines, side effect data, and a comparison of brand vs compounded options.
Semaglutide is the most widely prescribed GLP-1 receptor agonist for weight loss, and the clinical evidence behind it's extensive. You may know it by its brand names, Wegovy and Ozempic, or you may be considering compounded semaglutide as a more affordable alternative. Regardless of the formulation, the active molecule is the same.
Understanding semaglutide before and after data starts with the STEP clinical trial program. These four major studies enrolled thousands of participants and measured weight loss over more than a year. The results established semaglutide as one of the most effective non-surgical weight management tools available.
How Much Weight Do People Lose on Semaglutide?
The STEP-1 trial[1] demonstrated 14.9% average body weight loss with semaglutide 2.4 mg weekly over 68 weeks, compared to 2.4% with placebo. The study enrolled 1,961 adults[1] and was published in the New England Journal of Medicine. One-third of participants achieved weight loss of 20% or more.
For practical context, a 220-pound person losing 14.9% of body weight[1] would lose roughly 33 pounds. A 260-pound person would lose roughly 39 pounds. These are averages, and individual results range widely based on starting weight, adherence, lifestyle factors, and genetics.
| Trial | Population | Duration | Avg Loss (Semaglutide 2.4 mg) | Avg Loss (Placebo) |
|---|---|---|---|---|
| STEP-1 | Obesity, no diabetes (n=1,961) | 68 weeks | 14.9% | 2.4% |
| STEP-2[2] | Obesity + type 2 diabetes (n=1,210) | 68 weeks | 9.6% | 3.4% |
| STEP-3[3] | With intensive behavioral therapy (n=611) | 68 weeks | 16.0% | 5.7% |
| STEP-4[4] | Continuation vs withdrawal (n=902) | 68 weeks | Continued: additional 7.9% | Placebo switch: ~7% regain |
The response rates are equally important. In STEP-1, 86.4% of participants on semaglutide lost at least 5%[1] of body weight, 69.1% lost at least 10%, and 50.5% lost at least 15%. Those response rates are significantly higher than any previously approved weight loss medication.
What Is the Week-by-Week Semaglutide Timeline?
Semaglutide produces weight loss on a gradual curve, with the dose escalating from 0.25 mg to the full 2.4 mg over approximately 16 to 20 weeks. The most rapid weight loss typically occurs between months 3 and 8 of treatment. Appetite suppression begins almost immediately for most patients.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
The titration schedule exists to minimize gastrointestinal side effects. Starting at the full dose would cause severe nausea in most patients. The gradual approach lets your body adapt while still producing meaningful early results.
| Timeframe | Dose | What to Expect | Estimated Cumulative Loss |
|---|---|---|---|
| Weeks 1 to 4 | 0.25 mg | Subtle appetite changes. Body adjusting. Minimal weight loss. | 1 to 2% |
| Weeks 5 to 8 | 0.5 mg | Appetite suppression becomes noticeable. Portion sizes decrease naturally. | 2 to 4% |
| Weeks 9 to 12 | 1.0 mg | Clear weight loss underway. Clothes fit differently. Cravings reduce. | 4 to 7% |
| Weeks 13 to 16 | 1.7 mg | Entering rapid loss phase. Side effects begin stabilizing. | 6 to 9% |
| Weeks 17 to 20 | 2.4 mg | Full dose reached. Maximum appetite suppression. | 8 to 11% |
| Weeks 21 to 40 | 2.4 mg | Peak weight loss period. Significant body composition changes. | 11 to 15% |
| Weeks 41 to 68 | 2.4 mg | Loss slows toward plateau. Maintenance phase begins. | 14 to 17% |
Not everyone follows this exact timeline. Patients with type 2 diabetes tend to lose weight more slowly. Those with higher starting BMIs often see faster initial losses.
The key factor is consistency: staying on the medication and following through with lifestyle changes.
What Are Semaglutide Side Effects?
Gastrointestinal side effects are the most common and most discussed aspect of semaglutide treatment. In the STEP-1 trial, 44% of participants reported nausea, 30% diarrhea, 24% vomiting, and 24% constipation. These numbers are higher than those reported for tirzepatide in the SURMOUNT trials.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Context matters when reading those numbers. Most side effects were rated mild to moderate. They were concentrated during dose escalation periods and improved as the body adjusted.
Only 7% of participants discontinued semaglutide due to side effects.
| Side Effect | Semaglutide 2.4 mg | Placebo | Typical Duration |
|---|---|---|---|
| Nausea | 44% | 18% | 2 to 6 weeks per dose step |
| Diarrhea | 30% | 16% | 1 to 3 weeks |
| Vomiting | 24% | 6% | 1 to 2 weeks per dose step |
| Constipation | 24% | 11% | Variable, may persist |
| Abdominal pain | 20% | 11% | 2 to 4 weeks |
| Headache | 14% | 12% | 1 to 2 weeks |
| Fatigue | 11% | 5% | 2 to 4 weeks |
Strategies for managing side effects include eating smaller meals, avoiding high-fat foods during dose escalation, staying hydrated, and timing injections before bed so nausea occurs during sleep. Your prescribing physician can also slow the titration schedule if side effects are severe.
How Does Semaglutide Compare to Tirzepatide?
Tirzepatide (Mounjaro/Zepbound) has produced greater average weight loss in clinical trials: 20.9% vs 14.9% at their respective maximum doses. The difference is driven by tirzepatide's dual GIP/GLP-1 receptor mechanism versus semaglutide's GLP-1-only approach.
But semaglutide has several practical advantages. It has been on the market longer, with more published long-term safety data. Compounded semaglutide is available at a lower price point than compounded tirzepatide ($199/mo vs $249/mo at FormBlends).
And some patients simply respond better to semaglutide.
| Feature | Semaglutide 2.4 mg | Tirzepatide 15 mg |
|---|---|---|
| Mechanism | GLP-1 only | Dual GIP/GLP-1 |
| Avg weight loss | 14.9% | 20.9% |
| Nausea rate | 44% | 24% |
| Time on market | Since 2021 (weight loss) | Since 2023 (weight loss) |
| Compounded cost (FormBlends) | $199/mo | $249/mo |
| Long-term safety data | More extensive | Growing |
Neither medication is universally superior. The right choice depends on your health profile, budget, tolerance, and treatment goals. Compare all GLP-1 options without insurance here.
Compounded vs Brand-Name Semaglutide: What Is the Difference?
Compounded semaglutide contains compounded formulations of the active ingredient as Wegovy and Ozempic, prepared by a licensed compounding pharmacy rather than the brand-name manufacturer (Novo Nordisk). The FDA has permitted compounding of semaglutide during shortage periods, and compounding pharmacies operate under state and federal regulations with strict quality standards.
The primary difference is cost. Brand-name Wegovy runs approximately $1,300 per month without insurance. Compounded semaglutide through FormBlends is $199 per month, which includes the medication, physician consultation, and shipping.
| Feature | Wegovy (Brand) | Compounded Semaglutide (FormBlends) |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Monthly cost (no insurance) | ~$1,300 | $199 |
| Administration | Pre-filled pen | Vial + syringe or pen |
| Available doses | 0.25 to 2.4 mg | Custom dosing available |
| Physician oversight | Required | Included |
| Insurance accepted | Varies by plan | Not applicable (cash pay) |
| FDA-approved product | Yes | FDA-regulated compounding |
Compounded semaglutide is the most popular option for patients without insurance coverage or with high copays for brand-name products. The clinical approach is identical: same active ingredient, same dosing schedule, same physician supervision. Compare compounded semaglutide options and pricing here.
What Do the STEP Clinical Trials Show?
The STEP program comprises four landmark trials that collectively enrolled over 4,500 participants and established semaglutide as a first-line treatment for obesity. Each trial was placebo-controlled, double-blinded, and published in peer-reviewed journals including the New England Journal of Medicine and The Lancet.
STEP-1 set the benchmark: 14.9% average body weight loss with semaglutide 2.4 mg over 68 weeks. STEP-2 showed 9.6% loss in patients with type 2 diabetes[2]. STEP-3 demonstrated that adding intensive behavioral therapy boosted results to 16.0%.
And STEP-4 proved that stopping semaglutide leads to substantial weight regain.
The STEP-4 finding is critically important. Patients who continued semaglutide after an initial 20-week treatment period lost an additional 7.9% of body weight. Those who switched to placebo regained about two-thirds of their lost weight.
This data supports the medical consensus that obesity is a chronic disease requiring ongoing treatment, not a short-term condition that can be "cured" with a temporary medication course.
How to Maximize Semaglutide Results
STEP-3 showed that combining semaglutide with intensive behavioral therapy produced 16.0% body weight loss versus 14.9% with standard counseling alone. While one percentage point may sound small, it represents meaningful additional weight loss at scale and demonstrates that lifestyle factors matter even when medication is doing much of the heavy lifting.
The three most impactful lifestyle factors based on published data and our clinical experience at FormBlends are protein intake, resistance training, and sleep quality.
Protein first. Aim for 1.0 to 1.2 grams per kilogram of body weight daily, split across meals. This is the single most important dietary intervention for preserving lean muscle mass during GLP-1-mediated weight loss. Many patients undereat protein because their appetite is so suppressed.
Lift weights. Resistance training 2 to 3 times per week directly counteracts the lean mass loss that accompanies any significant weight reduction. You don't need a gym membership. Bodyweight exercises, resistance bands, or basic dumbbell routines all work.
Prioritize sleep. Poor sleep disrupts leptin and ghrelin, the hormones that regulate hunger and satiety. Patients who sleep less than 6 hours per night consistently see slower weight loss and more difficulty managing cravings, even on medication.
Model your projected timeline with the FormBlends weight loss calculator to set realistic monthly targets.
Frequently Asked Questions
What is the difference between semaglutide, Wegovy, and Ozempic?
Semaglutide is the active drug ingredient. Wegovy (semaglutide 2.4 mg) is FDA-approved for weight management. Ozempic (semaglutide 1.0/2.0 mg) is approved for type 2 diabetes but often prescribed off-label for weight loss.
Compounded semaglutide contains compounded formulations of the active ingredient from licensed compounding pharmacies.
How much weight can you lose on semaglutide?
The STEP-1 trial showed 14.9% average body weight loss over 68 weeks on semaglutide 2.4 mg. For a 220-pound person, that equals roughly 33 pounds. One-third of participants lost 20% or more of their starting weight.
How quickly does semaglutide work for weight loss?
Appetite changes typically begin within 1 to 2 weeks. Visible weight loss usually appears by weeks 4 to 8. Full therapeutic results take 6 to 12 months, as the dose is gradually escalated over the first 16 to 20 weeks.
Is compounded semaglutide as effective as Wegovy?
Compounded semaglutide contains compounded formulations of the active ingredient as Wegovy. When dosed at the same level (2.4 mg weekly) and obtained from a licensed compounding pharmacy, the clinical effect is expected to be equivalent. FormBlends works with pharmacies that undergo third-party purity testing.
What are semaglutide side effects?
The most common side effects are gastrointestinal: nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%) in the STEP-1 trial at the 2.4 mg dose. Side effects are typically worst during dose escalation and improve over time.
How much does compounded semaglutide cost?
Compounded semaglutide through FormBlends starts at $199 per month, compared to approximately $1,300 per month for brand-name Wegovy without insurance. The compounded version includes compounded formulations of the active ingredient with physician oversight and medication delivery.
What happens when you stop taking semaglutide?
Weight regain is common after stopping semaglutide. STEP-4 data showed patients who switched to placebo regained about two-thirds of their weight loss over 48 weeks. Most clinicians recommend ongoing treatment for sustained results.
Is semaglutide better than tirzepatide?
Tirzepatide has produced greater average weight loss in clinical trials: 20.9% vs 14.9%. But semaglutide has a longer track record, more published safety data, and is available at a lower price as compounded semaglutide. The best choice depends on your individual health profile, goals, and budget.
Medical References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
- Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021;325(14):1414-1425. [PubMed | ClinicalTrials.gov | DOI]
Research Snapshot
Provider comparisonEntities covered
Regulatory status, labels, trial records, and sponsor updates can change quickly for obesity-drug pipeline pages. This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision. Last page review: 2026-04-01.
Evidence standard
How this page was source-checked
FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.
FDA: unapproved GLP-1 drug safety concerns
RegulatorUsed for safety language around compounded, counterfeit, and unapproved GLP-1 products.
ADA Standards of Care in Diabetes 2026
GuidelineUsed for diabetes, cardiometabolic risk, and obesity-treatment context.
STEP 1 semaglutide obesity trial
TrialPrimary trial source for semaglutide 2.4 mg weight-loss expectations and side effects.
SURMOUNT-1 tirzepatide obesity trial
TrialPrimary trial source for tirzepatide weight-loss expectations and dose-response ranges.
PubMed evidence trail
Research sources used to frame this page
For Semaglutide Before and After: Real Weight Loss Results and Timeline [2026], FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight
Supports head-to-head context when pages compare older and newer GLP-1 options.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition
Supports body-composition, lean-mass, and metabolic-risk context.
PubMed
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
Used as a class-level evidence anchor when no more specific citation group matches.
PubMed
Comparison decision path
Use this comparison to narrow the provider review question
Direct answer
Semaglutide Before and After: Real Weight Loss Results and Timeline [2026] should help you decide which option deserves a clinical review, not force a one-size answer.
Evidence check
A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.
Safety check
The right choice can change based on history, medication interactions, side effects, budget, and availability.
Next step
After comparing, use the get-started flow to route your goals and health history into the right prescription review path.
FormBlends Editorial Context
Reviewed May 14, 2026Semaglutide before and after results from STEP trials show 14.9% average weight loss. Includes compounded vs brand comparison, dosing timeline, and real patient outcome data. Before you use "Semaglutide Before and After: Real Weight Loss Results and Timeline [2026]" to make a real decision, separate the headline answer from the details that could change it. The page connects patient education and clinical context with semaglutide, dosing, provider access, safety and pharmacy quality, inside a GLP-1 treatment guide where medication choice, dosing, side effects, monitoring, and insurance rules can change the decision. Because this article has 8 major sections, scan the headings first and then use the FAQ or summary sections to pressure-test the answer. Bring anything that changes dosing, pharmacy choice, cost, or safety to a licensed clinician.
- Confirm whether the page is discussing an FDA-approved use, a compounded option, or research-only context.
- Ask a licensed clinician how the evidence applies to your health history, medications, labs, and side-effect risk.
- Verify the pharmacy pathway, certificate of analysis, sterility testing, and clinician oversight before trusting a source.
Original tools and data
Use the FormBlends research stack
These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.
Editorial refresh
Practical 2026 note for Semaglutide Before and After
This update makes Semaglutide Before and After more specific by tying semaglutide, tirzepatide, retatrutide, cash-pay pricing, safety signals, before to the page's original clinical, cost, access, or comparison angle.
The goal is to make the article more useful for people who already know the headline question and need page-level specifics, not another interchangeable glp-1 weight loss summary.
For 2026 review, the content emphasizes current verification, treatment fit, and patient-safety questions that can be discussed with a qualified provider.
Custom 2026 image for Semaglutide Before and After, glp-1 weight loss, and better treatment decision-making.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.
Written by FormBlends Editorial Research
Prepared by FormBlends Editorial Research. Claims are checked against primary regulatory, trial, label, and public-health sources where available. Reviewed by FormBlends Medical Team for medical accuracy, sourcing, and patient-safety framing.